Multiple Myeloma

68284528MMY4006

Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma

A151804

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

A211901

Reaching Rural Cancer Survivors Who Smoke Using Test-Based Cessation Interventions

BB2121-EAP-001

Expanded Access Protocol (EAP) for Subjects Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

A Phase 3, Open-Label Study of Elranatamab Monotherapy versus Elotuzumab, Pomalidomide, Dexamethasone (EPd) or Pomalidomide, Brotezomib, Dexamethasone 9PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed/Refractory Multiple Myeloma who Received Prior Anti-CD38 Directed Therapy

EAA173

Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma

EAY191

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

GRAIL-MA-002

REACH Study: Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity (REACH/Galleri-Medicare study)

INCA-34176-357

A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

JCAR017-EAP-001

Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release

KT-US-472-0141

Expanded access to commercially out-of-specification brexucabtagene autoleucel for the treatment of adult patients diagnosed with an FDA approved labeled indication

KT-US-679-0788

A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants with Relapsed/Refractory Multiple Myeloma

WVU010922

Prospective Evaluation of Xerava (Eravacycline) Prophylaxis in Hematological Malignancy Patients with Prolonged Neutropenia

WVU020925

A Multicenter Phase II Study of Subcutaneous Blinatumomab for Treatment of Adult Patients with CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)